~~<i id='AE4A76949D'><strike id='AE4A76949D'><tt id='AE4A76949D'><pre id='AE4A76949D'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：Wikipedia 2025-09-30 16:29:46 - browse：58346

JOHNSON & JOHNSON HEADQUARTERS — Daniel Hulshizer/AP

Eight months into his tenure, Johnson & Johnson’s R&D chief is putting a big emphasis on medicines for cancer, treatment-resistant depression, and autoimmune disease.

To sharpen that focus, R&D chief John Reed told STAT that the company is de-emphasizing two areas that have been mainstays for the drug and medical device giant: infectious disease and vaccines, as well as medicines targeting kidney disease and rare eye conditions.

The disclosures were made in an interview ahead of an investor meeting Reed is leading Tuesday aimed at generating excitement about the company’s research and development efforts.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： How doctors and nurses shape Google's AI

hotspot

knowledge

hotspot

entertainment

focus

AdobeMorethan2.5yearsaftertheNationalInstitutesofHealthreceiveda$1billionmandatefromCongresstostudya

WSS

Takeaways from AdvaMed, the largest medical devices conference

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

A biotech analyst on neuroscience, placebo effect, not over

What to know about Virgin Galactic's 1st mission taking paying customers to space

Man killed during FBI raid in connection with threats against Biden, other officials

Massive project maps cells in human brain in unprecedented detail

focus

comprehensive

hotspot

BioMarin wins approval for gene therapy to treat hemophilia A

Methadone doses haven’t kept up in the age of fentanyl

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Naloxone nonprofit donates 200,000 doses after FDA approval

DIEP, the 'gold standard' of breast reconstruction, is under threat

Naloxone nonprofit donates 200,000 doses after FDA approval

Bright Health sells Medicare Advantage business to Molina

In same hospitals, Black patients receive fewer opioids than white patients

Drug repurposing or repositioning? The language matters

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

knowledge

Cancer cells are shown to suck energy source from immune cells

The best solution to the drug shortages problem

What's changing in Medicare's open enrollment this year?

Emergent cuts jobs, executive role in business shake

Eight reasons why you should get an updated Covid vaccine

Jack Smith previously got search warrant for Trump's Twitter, new court docs show

knowledge

hotspot

entertainment

focus